drugset / Trial / NCT01629849

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

NCT01629849

Phase 1 Completed 84 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, pharmacokinetics including posology, and pharmacodynamics of multiple rising doses of BI 1021958 in otherwise healthy mild asthmatic subjects

Timeline

Start
2012-07
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1021958 Unknown

Indications